All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
QuANTUM-First exploratory analysis: Quizartinib maintenance in patients with newly diagnosed FLT3-ITD AML
Bookmark this article
|
Patients with ND FLT3-ITD AML achieved improved outcomes when quizartinib was added to induction, consolidation, and maintenance therapy in the phase III QuANTUM-First trial (NCT02668653).1 With a focus on MRD status, an exploratory analysis from QuANTUM-First assessed the impact of quizartinib vs placebo maintenance therapy in this population (n = 208; 116 received quizartinib, 92 received placebo). Results were presented by Levis during the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
| Quizartinib vs placebo demonstrated higher OS (76.3% vs 67.9 at 48 months; HR, 0.683; 95% CI, 0.395–1.183) and RFS (67.1% vs 59.6% at 36 months; HR, 0.738; 95% CI, 0.442–1.230) and lower CIR rates (34.4% vs 25.9% at 36 months). |
| Among patients who received maintenance without prior allo-HSCT (n = 89), quizartinib vs placebo provided an OS benefit (median OS, NR vs 42.5 months), with a 60% reduction in the risk of death (HR, 0.401; 95% CI, 0.192–0.838). |
| Both MRD− and MRD+ patients experienced an OS benefit with quizartinib maintenance vs placebo. Median OS was NR in both arms in MRD− patients (HR, 0.438; 95% CI, 0.193–0.991) and 40.4 months vs in 21.9 months in MRD+ patients (HR, 0.606; 95% CI, 0.225–1.633). |
| In patients who received maintenance therapy without allo-HSCT, OS was higher with quizartinib vs placebo in MRD− patients (median OS, NR in both arms; HR 0.194; 95% CI, 0.056–0.676) and MRD+ patients (median OS, NR vs 42.5 months; HR, 0.411; 95% CI, 0.100–1.688). |
| This exploratory analysis shows that quizartinib maintenance improved survival outcomes in patients with ND FLT3-ITD AML and supports its use in induction, consolidation, and maintenance, regardless of MRD status. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ASH, American Society of Hematology; CI, confidence interval; CIR, cumulative incidence of relapse; FLT3-ITD, FMS-like tyrosine kinase 3 internal tandem duplication; HR, hazard ratio; MRD, measurable residual disease; ND, newly diagnosed; NR, not reached; OS, overall survival; RFS, relapse-free survival.
Levis M. Abstract #2890. QuANTUM-First: Effects of quizartinib (Q) on RFS, OS, CIR, and MRD in newly diagnosed (ND) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation (CONT) therapy (tx). 66th American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 8, 2024; San Diego, US.
Your opinion matters
42 votes - 8 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox